Skip to content

US · OVID · BIOTECHNOLOGY

Ovid Therapeutics Inc. (OVID) intrinsic value and stock valuation

$2.20as of 2026-11-21 · Mkt cap 490.86M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ovid Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values OVID with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OVID’s statements →

Ovid Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10036 ovidrx.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$7.25M-10.5% 5y CAGRd
20142025
Net income
-$-17.41M
20142025
Free cash flow
-$-38.33M
20142025
Total equity
$130.7M+24.5% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$7.25M$570K$390K$1.5M$208.4M
Operating income-$-42.44M-$-61.88M-$-59.28M-$-55.55M$124.2M
Net income-$-17.41M-$-26.43M-$-52.34M-$-54.17M$122.8M
EPSd-$-236.1K-$-372.73K-$-741.57K-$-769.24K$1.8M
Operating cash flow-$-38.33M-$-55.96M-$-45.78M-$-55.23M$118.6M
Capital expenditure$0.00-$-70K-$-140K-$-1.42M-$-190K
Free cash flow-$-38.33M-$-56.03M-$-45.92M-$-56.65M$118.4M
Total assets$150.9M$92.2M$144M$155.3M$194.5M
Total debt$13.4M$14.8M$16M$16.5M$0.00
Net debt$270K-$-11.55M-$-11.04M-$-28.33M-$-187.8M
Total equity$130.7M$68.2M$87.8M$132.3M$179.8M
Cash and short-term investments$69.6M$53.1M$105.8M$129M$187.8M
Income statement
20252024202320222021
Revenue$7.25M$570K$390K$1.5M$208.4M
Cost of revenue$300K$0.00$0.00$0.00$0.00
Gross profit$6.95M$570K$390K$1.5M$208.4M
Research and development expenses$25.6M$36.8M$28.6M$24.6M$46.9M
Selling, general and administrative expenses$24.1M$25.7M$29.6M$32.4M$37.2M
Other expenses-$-300K$0.00$1.5M$0.00$0.00
Operating expenses$49.4M$62.5M$59.7M$57.1M$84.2M
Cost and expenses$49.7M$62.5M$59.7M$57.1M$84.2M
Interest income$0.00$3.9M$4.9M$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$300K$610K$570K$1.38M$240K
Ebitda-$-17.11M-$-57.77M-$-57.01M-$-54.17M$124.5M
Operating income-$-42.44M-$-61.88M-$-59.28M-$-55.55M$124.2M
Total other income/expenses, net$25M$35.5M$6.94M$1.38M-$-50K
Income before tax-$-17.41M-$-26.43M-$-52.34M-$-54.17M$124.2M
Income tax expense$0.00$0.00$0.00$0.00$1.33M
Net income-$-17.41M-$-26.43M-$-52.34M-$-54.17M$122.8M
Weighted average shares outstanding$73.7M$70.9M$70.6M$70.4M$67.5M
Weighted average diluted shares outstanding$73.7M$70.9M$70.6M$70.4M$68.1M
Balance sheet
20252024202320222021
Cash and short-term investments$69.6M$53.1M$105.8M$129M$187.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$90.5M$55.9M$109.6M$131.4M$190.5M
Property, plant and equipment, net$0.00$13.2M$14.7M$16.1M$240K
Goodwill and intangible assets$0.00$90K$200K$220K$160K
Long-term investments$64.7M$21M$17.6M$5.62M$3.56M
Total non-current assets$60.5M$36.2M$34.4M$23.9M$4.07M
Total assets$150.9M$92.2M$144M$155.3M$194.5M
Accounts payable$1.96M$3.19M$3.7M$1.95M$7.13M
Short-term debt$1.43M$1.34M$1.25M$530K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.29M$10.5M$11.5M$6.99M$14.8M
Long-term debt$12M$13.4M$14.8M$16M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$12M$13.4M$44.8M$16M$0.00
Capital lease obligations$13.4M$14.8M$16M$16.5M$0.00
Total liabilities$20.3M$23.9M$56.2M$23M$14.8M
Common stock$130K$70K$70K$70K$70K
Retained earnings-$-321.71M-$-304.3M-$-277.87M-$-225.53M-$-171.36M
Accumulated other comprehensive income (loss)-$-200K-$-30K$0.00-$-40K$0.00
Total equity$130.7M$68.2M$87.8M$132.3M$179.8M
Total investments$121.2M$47.8M$96.4M$89.8M$3.56M
Total debt$13.4M$14.8M$16M$16.5M$0.00
Net debt$270K-$-11.55M-$-11.04M-$-28.33M-$-187.8M
Cash flow statement
20252024202320222021
Net income-$-17.41M-$-26.43M-$-52.34M-$-54.17M$119.8M
Depreciation and amortization$270K$610K$1.6M$1.38M$240K
Stock-based compensation$4.81M$6.28M$7.29M$6.56M$0.00
Change in working capital-$-4.1M-$-150K$2.39M-$-8.23M-$-16.81M
Accounts receivable$0.00$0.00$0.00$0.00$140K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.23M-$-510K$1.75M-$-5.17M$1.7M
Net cash provided by operating activities-$-38.33M-$-55.96M-$-45.78M-$-55.23M$118.6M
Investments in property, plant and equipment$0.00-$-70K-$-40K-$-1.42M-$-180K
Acquisitions, net$0.00$0.00-$-10M-$-2.5M-$-1.63M
Net cash used for investing activities-$-49.85M$54.6M-$-2.58M-$-87.88M-$-1.82M
Common stock issued$75.2M$620K$540K$180K$930K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$75.2M$620K$30.5M$180K$900K
Net change in cash-$-13.15M-$-740K-$-17.83M-$-142.93M$115.8M
Cash at end of period$15.1M$28.2M$29M$46.8M$187.8M
Operating cash flow-$-38.33M-$-55.96M-$-45.78M-$-55.23M$118.6M
Capital expenditure$0.00-$-70K-$-140K-$-1.42M-$-190K
Free cash flow-$-38.33M-$-56.03M-$-45.92M-$-56.65M$118.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ovid Therapeutics Inc.

        Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

        CEO
        Margaret Alexander
        Employees
        23
        Beta
        0.23

        Explore

        Frequently asked questions

        What is the intrinsic value of Ovid Therapeutics Inc. (OVID)?

        InvestorsCraft does not currently publish an intrinsic value for OVID. How the IC value is calculated.

        Is OVID undervalued?

        InvestorsCraft does not publish an undervaluation signal for OVID at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.